Does the Urinary Mast Cell Mediators Predict the Immune Response
to BCG in Patients with Primary High-Grade Non-Muscle Invasive Bladder
Cancer?
Keywords: BCG; bladder cancer; immunotherapy; mast cell;
mediator
Running Title: Mast Cell Mediators in Bladder Cancer
- Muhammed Fatih Simsekoglu, Department of Urology, University of
Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
- Islim Kaleler, Department of Biochemistry, University of
Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
- Bulent Onal, Department of Urology, University of Istanbul-Cerrahpasa,
Cerrahpasa School of Medicine, Istanbul, Turkey
- Cetin Demirdag, Department of Urology, University of
Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
- Sinharib Citgez, Department of Urology, University of
Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
- Ezel Uslu, Department of Biochemistry, University of
Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
- Ahmet Erozenci, Department of Urology, University of
Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
- Zubeyr Talat, Department of Urology, University of
Istanbul-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
Conflict of interest : The authors declare that they have no
conflict of interest.
Funding source : This study was conducted with the financial
support of the Istanbul University-Cerrahpasa Board of Scientific
Research Projects (Number: 30651)Ethical approval: This study was approved by the institutional
review board of Istanbul University-Cerrahpasa.
Informed consent: Informed consent was obtained from all
individual participants included in the study.
Contribution statement: All authors contributed the study.
Data Availability statements: The datasets generated during
and/or analyzed during the current study are not publicly available due
(Personal Data Protection Law) but are available from the corresponding
author on reasonable request.